Another Duchenne Treatment Gets FDA Nod

(MedPage Today) -- Casimersen (Amondys 45) is approved to treat Duchenne muscular dystrophy (DMD) patients with a confirmed mutation amenable to exon 45 skipping, the FDA announced Thursday.
Like two other exon-skipping RNA therapies for DMD approved...